INHIBRX BIOSCIENCES, INC. Cash and Restricted Cash
INHIBRX BIOSCIENCES, INC. (INBX) had Cash and Restricted Cash of $133.34 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-13
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $133.34M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $161.66M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $124.22M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $153.09M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $133.34M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $161.66M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $124.22M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $153.09M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $186.57M 10-Q · filed 2026-08-13 |
| 2025-03-31 | $216.52M 10-Q · filed 2026-05-14 |
| 2024-12-31 | $152.60M 10-Q · filed 2026-08-13 |
| 2024-09-30 | $196.33M 10-Q · filed 2025-11-14 |
| 2024-06-30 | $226.86M 10-Q · filed 2025-08-13 |
| 2024-03-31 | $252.48M 10-Q · filed 2025-05-14 |
| 2023-12-31 | $277.92M 10-K · filed 2026-03-19 |
| 2023-09-30 | $337.33M 10-Q · filed 2024-11-14 |
| 2023-06-30 | $192.49M 10-Q · filed 2024-08-13 |
| 2022-12-31 | $273.87M 10-K · filed 2025-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |